Abstract:Optimal protein function often depends on co-operative interactions between amino acid residues distant in the protein primary sequence yet spatially near one another following protein folding. For example, antibody affinity is influenced by interactions of framework residues with complementarity-determining region (CDR) residues. However, despite the abundance of antibody structural information and computational tools the humanization of rodent antibodies for clinical use often results in a significant loss of affinity. To date, antibody engineering efforts have focused either on optimizing CDR residues involved in antigen binding or on optimizing antibody framework residues that serve critical roles in preserving the conformation of CDRs. In the present study a new approach which permits the rapid identification of co-operatively interacting framework and CDR residues was used to simultaneously humanize and optimize a murine antibody directed against CD40. Specifically, a combinatorial library that examined eight potentially important framework positions concomitantly with focused CDR libraries consisting of variants containing random single amino acid mutations in the third CDR of the heavy and light chains was expressed. Multiple anti-CD40 Fab variants containing as few as one murine framework residue and displaying up to approximately 500-fold higher affinity than the initial chimeric Fab were identified. The higher affinity humanized variants demonstrated a co-operative interaction between light chain framework residue Y49 and heavy chain CDR3 residue R/K101 (coupling energy, DeltaGI=0.9 kcal/mol). Screening of combinatorial framework-CDR libraries permits identification of monoclonal antibodies (mAb) with structures optimized for function, including instances in which the antigen induces conformational changes in the mAb. Moreover, the enhanced humanized variants contain fewer murine framework residues and could not be identified by sequential in vitro humanization and affinity muturation strategies. This approach to identifying co-operatively interacting residues is not restricted to antibody-antigen interactions and consequently, may be used broadly to gain insight into protein structure-function relationships, including proteins that serve as catalysts.

Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development

Preparation and characterization of a novel monoclonal antibody against human PD-1

A Glycoengineered Therapeutic Anti-Hbv Antibody That Allows Increased HBsAg Immunoclearance Improves HBV Suppression in Vivo

Humanization of Therapeutic Antibody of One Hepatitis B Virus and Identification of Its Biological Activity

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice

A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

Development of monoclonal antibodies against PD-L1 and preliminary investigation on potential application in treatment of chronic hepatitis B virus in-fection

Humanization and characterization of a murine monoclonal neutralizing antibody against human adenovirus 7

The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice.

Structural Insight into a Matured Humanized Monoclonal Antibody HuA21 Against HER2-overexpressing Cancer Cells.

Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.

Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants

Antibody-mediated immunotherapy against chronic hepatitis B virus infection.

Affinity Improvement of a Humanized Antiviral Antibody by Structure-Based Computational Design

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice

In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies